September 3, 2013 – Royal Philips Electronics (Philips) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EPIQ, an ultrasound system with Anatomical Intelligence, providing organ modeling, image slicing, and quantification.
Making its debut at the European Society of Cardiology (ESC) 2013 Congress in Amsterdam, EPIQ features a new imaging technology called nSIGHT that when combined with Philips' Anatomical Intelligence technology, delivering modeling, image slicing, and quantification for making exams easier to perform, more reproducible, and delivering new levels of clinical information.
- Philips receives 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its innovative EPIQ ultrasound system in the U.S.
Combining this intelligent technology with the precision clarity of nSIGHT Imaging makes for a faster more intuitive ultrasound system.
The EPIQ platform supports segment specific innovations for cardiology, radiology, OB/GYN and general imaging. The xMATRIX 3DTEE and the Anatomically Intelligent Mitral Valve Navigator A.I. provides a LIVE 3D planning solution that allows physicians to make more informed decisions before and during heart valve procedures. nSIGHT Imaging technology is designed to provide highly detailed ultrasound images and extraordinary temporal resolution.
For more information: www.healthcare.philips.com and www.appliedradiology.com